Balyasny Asset Management LLC Ionis Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $39.3 Million - $51.4 Million	1,077,321 New	1,077,321 $51.3 Million
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $2.7 Million - $3.36 Million	-77,616 Reduced 38.15%	125,850 $5.16 Million
Q1 2023 May 15, 2023	BUY	$33.58 - $41.2 $6.83 Million - $8.38 Million	203,466 New	203,466 $7.27 Million
Q2 2022 Aug 15, 2022	BUY	$31.71 - $43.0 $4.93 Million - $6.69 Million	155,533 New	155,533 $5.76 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $5.77 Million - $7.15 Million	-193,120 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$25.61 - $35.1 $1.31 Million - $1.79 Million	51,105 Added 35.99%	193,120 $5.88 Million
Q3 2021 Nov 15, 2021	SELL	$33.54 - $40.55 $4.07 Million - $4.92 Million	-121,271 Reduced 46.06%	142,015 $4.76 Million
Q2 2021 Aug 16, 2021	BUY	$34.54 - $47.25 $9.09 Million - $12.4 Million	263,286 New	263,286 $10.5 Million
Q1 2021 May 17, 2021	SELL	$42.51 - $63.78 $1.91 Million - $2.86 Million	-44,848 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$45.3 - $60.27 $2.03 Million - $2.7 Million	44,848 New	44,848 $2.54 Million
Q4 2019 Feb 14, 2020	SELL	$53.85 - $65.27 $13.6 Million - $16.5 Million	-253,265 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$59.06 - $72.15 $15 Million - $18.3 Million	253,265 New	253,265 $15.2 Million
Q1 2018 May 15, 2018	SELL	$44.08 - $55.05 $551,000 - $688,125	-12,500 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $372,220 - $476,486	7,400 Added 145.1%	12,500 $629,000
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $232,356 - $303,807	5,100	5,100 $259,000

402

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.46B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.